<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03570892</url>
  </required_header>
  <id_info>
    <org_study_id>CCTL019H2301</org_study_id>
    <secondary_id>2016-002966-29</secondary_id>
    <nct_id>NCT03570892</nct_id>
  </id_info>
  <brief_title>Tisagenlecleucel in Adult Patients With Aggressive B-cell Non-Hodgkin Lymphoma</brief_title>
  <acronym>BELINDA</acronym>
  <official_title>Tisagenlecleucel Versus Standard of Care in Adult Patients With Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma: A Randomized, Open Label, Phase III Trial (BELINDA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, open label, multicenter phase III trial comparing the efficacy, safety,
      and tolerability of tisagenlecleucel to Standard Of Care in adult patients with aggressive
      B-cell Non-Hodgkin Lymphoma after failure of rituximab and anthracycline containing frontline
      immunochemotherapy.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 7, 2019</start_date>
  <completion_date type="Anticipated">March 31, 2026</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2025</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized, Open-Label</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Event-free survival (EFS)</measure>
    <time_frame>5 years</time_frame>
    <description>Event-free survival (EFS) is defined as the time from the date of randomization to the date of the first documented disease progression or stable disease at or after the week 12 (+/- 1 week) assessment, as assessed by Blinded Independent Review Committee (BIRC) per Lugano criteria, or death due to any cause, at any time.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>EFS as assessed by local investigator</measure>
    <time_frame>5 years</time_frame>
    <description>EFS as assessed by local investigator</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>5 years</time_frame>
    <description>Overall survival (OS) is defined as the time from date of randomization to date of death due to any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate (ORR)</measure>
    <time_frame>5 years</time_frame>
    <description>Overall Response Rate (ORR) as per the Lugano criteria as per BIRC review and local investigator assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>5 years</time_frame>
    <description>Duration of response: time from the date of first documented response of CR or PR to the date of first documented progression (SD or PD at or after the week 12 assessment will be considered progression) or death due to aggressive B-cell NHL. DOR will be summarized by BIRC and local response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Response (TTR)</measure>
    <time_frame>5 years</time_frame>
    <description>Time from the date of randomization to the date of a patient's first achieved a response of CR or PR on or after the Week 12 assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SF-36v2</measure>
    <time_frame>5 years</time_frame>
    <description>Time to definitive deterioration in SF-36v2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FACT-Lym</measure>
    <time_frame>5 years</time_frame>
    <description>Time to definitive deterioration in FACT-Lym</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EQ-VAS</measure>
    <time_frame>5 years</time_frame>
    <description>Time to definitive deterioration in EQ-VAS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tisagenlecleucel transgene concentrations</measure>
    <time_frame>5 years</time_frame>
    <description>qPCR will be used to measure tisagenlecleucel transgene concentrations in peripheral blood and bone marrow</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tisagenlecleucel immunogenicity (humoral and cellular)</measure>
    <time_frame>5 years</time_frame>
    <description>Pre-existing and treatment related immunogenicity (humoral and cellular) of tisagenlecleucel will be characterized.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of replication competent lentivirus (RCL)</measure>
    <time_frame>5 years</time_frame>
    <description>The presence of RCL will be assessed by VSV-qPCR in patients receiving tisagenlecleucel</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">318</enrollment>
  <condition>Non-Hodgkin Lymphoma</condition>
  <arm_group>
    <arm_group_label>Tisagenlecleucel treatment strategy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive investigator's choice of optional platinum-based immunochemotherapy followed by lymphodepleting chemotherapy and a single dose of tisagenlecleucel</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of care treatment strategy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive investigator's choice of platinum-based immunochemotherapy followed in responding patients by high dose chemotherapy and autologous hematopoietic stem cell transplant (HSCT)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tisagenlecleucel after optional bridging and lymphodepleting chemotherapy</intervention_name>
    <description>Investigator's choice of optional platinum-based immunochemotherapy (ie. R-ICE, R-GemOx, R-GDP, R-DHAP) + Lymphodepleting chemotherapy (fludarabine with cyclophosphamide or bendamustine) + Tisagenlecleucel (a second generation CAR-T composed of a CD19 antigen-binding domain, a 4-1BB costimulatory domain and a CD3-ζ signaling domain)</description>
    <arm_group_label>Tisagenlecleucel treatment strategy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Platinum-based immunochemotherapy followed in responding patients with high dose chemotherapy and autologous hematopoietic stem cell transplant (HSCT)</intervention_name>
    <description>Investigator's choice of platinum-based immunochemotherapy (ie. R-ICE, R-GemOx, R-GDP, R-DHAP)+ High dose chemotherapy (ie. BEAM) + autologous HSCT.
*Ibrutinib or lenalidomide may be used in patients who are no longer eligible for autologous HSCT after 2 cycles of immunochemotherapy</description>
    <arm_group_label>Standard of care treatment strategy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Histologically confirmed, aggressive B-cell NHL at relapse/progression or PR after
             front line therapy. Aggressive B-cell NHL is heretofore defined by the following list
             of subtypes (Swerdlow et al 2016):

               1. DLBCL, NOS,

               2. FL grade 3B,

               3. Primary mediastinal large B cell lymphoma (PMBCL),

               4. T cell rich/histiocyte rich large B cell lymphoma (T/HRBCL),

               5. DLBCL associated with chronic inflammation,

               6. Intravascular large B-cell lymphoma,

               7. ALK+ large B-cell lymphoma,

               8. B-cell lymphoma, unclassifiable, (with features intermediate between DLBCL and
                  classical Hodgkin's Lymphoma (HL)),

               9. High grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements,

              10. High-grade B-cell lymphoma, NOS

              11. HHV8+ DLBCL, NOS

              12. DLBCL transforming from follicular lymphoma

              13. DLBCL transforming from marginal zone lymphoma

              14. DLBCL, leg type

          2. Relapse or progression within 365 days from last dose of anti CD20 antibody and
             anthracycline containing first line immunochemotherapy or refractory (have not
             achieved a CR).

          3. Patient is considered eligible for autologous HSCT as per local investigator
             assessment. Note: Intention to transplant and type of high dose chemotherapy (HDCT)
             regimen will be documented at the time of study entry

          4. Disease that is both active on PET scan (defined as 5-Deauville scorepoint-scale of 4
             or 5) and measurable on CT scan, defined as::

               1. Nodal lesions &gt;15 mm in the long axis, regardless of the length of the short
                  axis, and/or

               2. Extranodal lesions (outside lymph node or nodal mass, but including liver and
                  spleen) &gt;10 mm in long AND short axis

          5. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1

          6. Adequate organ function:

             Renal function defined as:

               1. Serum creatinine of ≤1.5 x upper limit of normal (ULN), OR estimated glomerular
                  filtration rate (eGFR) ≥ 60 mL/min/1.73 m2

                  Hepatic function defined as:

               2. Alanine Transaminase (ALT) and Aspartate Transiminase (AST) ≤ 5 × ULN

               3. Total bilirubin ≤ 1.5 x ULN with the exception of patients with Gilbert syndrome
                  who may be included if their total bilirubin is ≤3.0 × ULN and direct bilirubin
                  ≤1.5 × ULN

                  Hematologic Function (regardless of transfusions) defined as:

               4. Absolute neutrophil count (ANC) &gt;1000/mm3

               5. Absolute lymphocyte count (ALC) &gt;300/mm3 OR Absolute number of CD3+ T cells
                  &gt;150/mm3 (only for patients with non-historical apheresis)

               6. Platelets ≥50000/mm3

               7. Hemoglobin &gt;8.0 g/dl

                  Adequate pulmonary function defined as:

               8. No or mild dyspnea (≤ Grade 1)

               9. Oxygen saturation measured by pulse oximetry &gt; 90% on room air

              10. Forced expiratory volume in 1 s (FEV1) ≥ 50% and/or carbon monoxide diffusion
                  test (DLCO) ≥50% of predicted level

          7. Must have a leukapheresis material of non-mobilized cells available for manufacturing.

        Exclusion Criteria:

          1. Prior treatment with anti-CD19 therapy, T cell therapy, or any prior gene therapy
             product

          2. Treatment with any systemic lymphoma-directed second line anticancer therapy prior to
             randomization. Only steroids and local irradiation are permitted for disease control

          3. Patients with active central nervous system (CNS) involvement by disease under study
             are excluded, except if the CNS involvement has been effectively treated and local
             treatment was &gt;4 weeks before randomization

          4. Prior allogeneic HSCT

          5. Clinically significant active infection

          6. Any of the following cardiovascular conditions:

               -  Unstable angina, myocardial infarction, coronary artery bypass graft (CABG), or
                  stroke within 6 months prior to screening,

               -  Left ventricle ejection fraction (LVEF) &lt;45% as determined by echocardiogram
                  (ECHO) or magnetic resonance angiography (MRA) or multigated acquisition (MUGA)
                  at the screening assessment.

               -  New York Heart Association (NYHA) functional class III or IV (Chavey et al 2001),
                  within the past 12 months.

               -  Clinically significant cardiac arrhythmias (e.g., ventricular tachycardia),
                  complete left bundle branch block, high-grade atrioventricular (AV) block (e.g.,
                  bifascicular block, Mobitz type II) and third degree AV block unless adequately
                  controlled by pacemaker implantation.

               -  Resting QTcF ≥450 msec (male) or ≥460 msec (female) at screening or inability to
                  determine the QTcF interval

               -  Risk factors for Torsades de Pointes (TdP), including uncorrected hypokalemia or
                  hypomagnesemia, history of cardiac failure, or history of clinically significant/
                  symptomatic bradycardia, or any of the following:

               -  Long QT syndrome, family history of idiopathic sudden death or congenital long QT
                  syndrome

               -  Concomitant medication(s) with a &quot;Known Risk of Torsades de Pointes&quot; per
                  crediblemeds.org that cannot be discontinued or replaced by safe alternative
                  medication.

          7. Patients with active neurological autoimmune or inflammatory disorders (e.g.,
             Guillain-Barré Syndrome (GBS), Amyotrophic Lateral Sclerosis (ALS)) and clinically
             significant active cerebrovascular disorders (e.g. cerebral edema, posterior
             reversible encephalopathy syndrome (PRES))

        Other protocol-defined inclusion and exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>1-888-669-6682</phone>
    <email>novartis.email@novartis.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>+41613241111</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Moores UC San Diego Cancer Center</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Viktoriya Duda</last_name>
      <phone>858-822-5364</phone>
      <email>vduda@ucsd.edu</email>
    </contact>
    <investigator>
      <last_name>Carolyn Mulroney</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California Los Angeles University of California LA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gina Khachatrian</last_name>
      <phone>310-825-7412</phone>
      <email>GKhachatrian@mednet.ucla.edu</email>
    </contact>
    <investigator>
      <last_name>Herbert Eradat</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UCSF Medical Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charlie Aoun</last_name>
      <phone>415-353-1351</phone>
      <email>charlie.aoun@ucsf.edu</email>
    </contact>
    <investigator>
      <last_name>Charalambos Andreadis</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Caleb Cleveland</last_name>
      <phone>720-754-4800</phone>
      <email>caleb.cleveland@sarahcannon.com</email>
    </contact>
    <investigator>
      <last_name>Peter McSweeney</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Jacksonville</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brittany Mason</last_name>
      <phone>904-953-6806</phone>
      <email>Mason.Brittany@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Mohamed Kharfan Dabaja</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emory University School of Medicine/Winship Cancer Institute SC</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Deanna Hill</last_name>
      <email>dmhill@emory.edu</email>
    </contact>
    <investigator>
      <last_name>Jonathon Cohen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Chicago Medical Center Hematology and Oncology</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>773-834-8980</phone>
    </contact>
    <investigator>
      <last_name>Michael R. Bishop</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Kansas Cancer Center SC</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dana Wheeler</last_name>
      <email>dwheeler2@kumc.edu</email>
    </contact>
    <investigator>
      <last_name>Joseph P McGuirk</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wayne State University - Karmanos Cancer Institute SC</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Suanne Minh Dorr</last_name>
      <phone>313-576-9271</phone>
      <email>dorrs@karmanos.org</email>
    </contact>
    <investigator>
      <last_name>Abinav Deol</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Nebraska Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maribeth Hohenstein</last_name>
      <phone>402-559-6275</phone>
      <email>mahohens@unmc.edu</email>
    </contact>
    <investigator>
      <last_name>Julie M. Vose</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>201-996-2000</phone>
    </contact>
    <investigator>
      <last_name>Lori Leslie</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bonnie Toaso</last_name>
      <phone>919-681-4769</phone>
      <email>bonnie.toaso@duke.edu</email>
    </contact>
    <investigator>
      <last_name>Matthew S. McKinney</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jewish Hospital</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45236</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alessa Hubbell</last_name>
      <phone>513-794-5482</phone>
      <email>Alessa.Hubell@usonoclogy.com</email>
    </contact>
    <investigator>
      <last_name>James H Essell</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Ohio State University SC</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heather Heise</last_name>
      <phone>614-366-7421</phone>
      <email>CTO.Implementation@osumc.edu</email>
    </contact>
    <investigator>
      <last_name>David A Bond</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oregon Health Sciences Univ SC</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacqueline Brown</last_name>
      <phone>503-494-4603</phone>
      <email>brownjacq@ohsu.edu</email>
    </contact>
    <investigator>
      <last_name>Richard T. Maziarz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania, Abramson Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brittany Koch</last_name>
      <phone>215-662-6394</phone>
      <email>brittany.koch@uphs.upenn.edu</email>
    </contact>
    <investigator>
      <last_name>Stephen Schuster</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MUSC Hollings Cancer Center</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shanta Salzer</last_name>
      <email>salzers@musc.edu</email>
    </contact>
    <investigator>
      <last_name>Brian Hess</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Renee Thompson</last_name>
      <email>renee.thompson@sarahcannon.com</email>
    </contact>
    <investigator>
      <last_name>Ian W. Flinn</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baylor Scott and White Research Institute</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joyce Ghormley</last_name>
      <phone>214-987-6915</phone>
      <email>Joyce.Ghormley@BSWHealth.org</email>
    </contact>
    <investigator>
      <last_name>Houston Holmes</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas MD Anderson Cancer Center MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katherine Annandale</last_name>
      <phone>713-792-2860</phone>
      <email>kannanda@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Jason Westin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Methodist Hospital</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>George DeLeon</last_name>
      <phone>210-575-3817</phone>
      <email>George.deleon@mhshealth.com</email>
    </contact>
    <investigator>
      <last_name>Paul Shaughnessy</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin Carbone Cancer Center</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792-6164</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>608-265-3794</phone>
    </contact>
    <investigator>
      <last_name>Vaishalee Kenkre</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Darlinghurst</city>
        <state>New South Wales</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Murdoch</city>
        <state>Western Australia</state>
        <zip>6150</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Innsbruck</city>
        <zip>A-6020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Salzburg</city>
        <zip>5020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Vienna</city>
        <zip>A-1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sao Paulo</city>
        <zip>05651-901</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lille Cedex</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Montpellier cedex 5</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nantes Cedex 1</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pierre Benite Cedex</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Regensburg</city>
        <state>Bavaria</state>
        <zip>93053</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Koeln</city>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Muenchen</city>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rozzano</city>
        <state>MI</state>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Roma</city>
        <state>RM</state>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kyushu University Hospital</name>
      <address>
        <city>Fukuoka city</city>
        <state>Fukuoka</state>
        <zip>812-8582</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hokkaido University Hospital</name>
      <address>
        <city>Sapporo city</city>
        <state>Hokkaido</state>
        <zip>060 8648</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tohoku University Hospital</name>
      <address>
        <city>Sendai city</city>
        <state>Miyagi</state>
        <zip>980 8574</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Amsterdam UMC, locatie AMC</name>
      <address>
        <city>Amsterdam</city>
        <zip>1105 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>M.J. Kersten</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UMC Utrecht Cancer Center</name>
      <address>
        <city>Utrecht</city>
        <zip>3584CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>M.C. Minnema</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Oslo</city>
        <zip>NO-0424</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Singapore</city>
        <zip>119228</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Singapore</city>
        <zip>169608</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <state>Catalunya</state>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hospitalet de LLobregat</city>
        <state>Catalunya</state>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Madrid</city>
        <zip>28009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Zurich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Brazil</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hong Kong</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Netherlands</country>
    <country>Norway</country>
    <country>Singapore</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>June 18, 2018</study_first_submitted>
  <study_first_submitted_qc>June 18, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 27, 2018</study_first_posted>
  <last_update_submitted>July 23, 2020</last_update_submitted>
  <last_update_submitted_qc>July 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Non-Hodgkin's Lympoma</keyword>
  <keyword>B-Cell Lymphoma</keyword>
  <keyword>Diffuse Large B-cell Lymphoma</keyword>
  <keyword>High Grade B-cell Lymphoma</keyword>
  <keyword>Follicular Lymphoma grade 3B</keyword>
  <keyword>CAR-T</keyword>
  <keyword>Tisagenlecleucel</keyword>
  <keyword>Kymriah</keyword>
  <keyword>Immunotherapy</keyword>
  <keyword>Cellular therapy</keyword>
  <keyword>CTL019</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent expert panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
This trial data is currently available according to the process described on www.clinicalstudydatarequest.com.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

